Sebastiaan Vastert, MD, PhD

University Medical Center Utrecht
Utrecht, Netherlands

Bas Vastert (1975) is a pediatric rheumatologist in the Wilhelmina Children’s Hospital Utrecht. He obtained his PhD on mechanisms of disease and therapy in severe Juvenile Idiopathic Arthritis in 2013. From 2013, he started a translational research line in the laboratory of translational immunology and from March 2017 he is co-heading the v Loosdregt-Vastert group within the Laboratory of Translational Immunology in UMC Utrecht, focusing on novel therapeutic strategies in JIA through translation of cutting edge basic science into clinical benefit.
He is currently leading a multi-center prospective trial implementing a biomarker driven stop-strategy for rIL-1RA therapy in systemic JIA in the Netherlands and setting up a clinical trial studying the potential of Nicotinamide (vitamin B3) in therapeutic strategies for non-systemic JIA.

Disclosure information not submitted.

Presentation(s):

• 569: CH Pediatrics: PReS-CARRA Collaborations: Part I

  Sunday, November 13, 2022
  1:00 PM – 1:45 PM Eastern Time

• L12: First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time

• L12: First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background

  Monday, November 14, 2022
  2:25 PM – 2:30 PM Eastern Time